AIMdex is an immunological function assay kit. It reflects the activity of CD4 T cells by measuring the level of ATP release from CD4⁺T cells after stimulation. The principle is based on the fact that when immune cells are stimulated by antigen, they increase the synthesis and release of ATP through various pathways (such as activation of cell membrane receptors, signaling pathways, etc.), increase ATP synthesis and release, leading to an increase in intracellular ATP concentration.

The detection method utilizes a luciferase assay, which involves the successful development and in-house production of key materials such as PHA, CD4 antibody-coupled magnetic beads, and a bioluminescent agent. This achievement represents a breakthrough in domestically produced immunological cell response function detection reagents. In addition, the AIMdex series also includes the CD8⁺ T cell ATP release assay detection kit and the NK cell ATP release assay detection kit.

① A domestically pioneered assay kit for direct, quantitative, and accurate evaluation of CD4 T cell immune response capability;

② Rigorous performance validation has allowed us to establish a reliable reference range;

③ It aligns with the FDA's only approved cellular immune function detection method, demonstrating high accuracy and reliability;

④ Key technological breakthroughs have eliminated reliance on imported or domestic suppliers for reagents, resulting in cost reduction and improved market competitiveness.

AIMdex is an immune function monitoring tool that can be used to assess and monitor immune function in clinical patients and physical examination populations. The main uses include health management, clinical immune monitoring.

① Health management: AIMdex can be used for health management to help people understand their immune status, develop a health plan, and improve immunity and health;

② Clinical immune monitoring: During treatment, AIMdex can monitor changes in immune function, assess the treatment effect and guide the adjustment of subsequent treatment plans.

a) In the field of solid organ transplantation and hematopoietic stem transplantation: to predict the risk of infection and rejection, the basis for regulation of immunosuppressant use;

b) Solid tumor and hematologic tumor field: dynamic monitoring of immune response function throughout the treatment cycle of tumor patients, providing scientific basis for the assessment of treatment efficacy and risk of adverse prognosis occurrence;

c) Critical infections: dynamic monitoring of immune function to provide a basis for immune-related early warning for patients with critical infections;

d) Autoimmune diseases: to predict the risk of infection and provide an auxiliary basis for the regulation of immunosuppressant use.